|
| Press Releases |
|
 |
|
| Friday, July 31, 2015 |
|
|
Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and Pegph20 in Advanced Breast Cancer |
Eisai Co., Ltd. and Halozyme Therapeutics, Inc. announced today that they have signed a clinical collaboration agreement to evaluate Eisai's
anticancer agent eribulin mesylate in combination with Halozyme's investigational new drug PEGPH20 in first line HER2-negative advanced breast cancer. more info >> |
|
|
Continuation of "Policy for Protection of The Company's Corporate Value and Common Interests of Shareholders (Shareholder Rights Plan)" |
| The Board of Directors of Eisai Co., Ltd. passed a resolution for the continuation of the "Policy for Protection of the Company's Corporate Value and Common Interests of Shareholders", which was proposed by the Independent Committee of Outside Directors at its meeting held today. more info >> |
|
| Wednesday, July 29, 2015 |
|
|
Eisai's In-House Developed Novel Anticancer Agent Lenvima Receives Breakthrough Therapy Designation From U.S. Fda for Renal Cell Carcinoma |
| Eisai Co., Ltd. announced today its U.S. subsidiary Eisai Inc. has received a Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for its in-house developed novel anticancer agent Lenvima for the potential indication of advanced and/or metastatic renal cell carcinoma. more info >> |
|
| Friday, June 26, 2015 |
|
|
Eisai to Launch New Fine Granule Formulation of Tachyarrhythmia Treatment Tambocor Suitable for Pediatric Patients in Japan |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it will launch Tambocor Fine Granules 10%, a new formulation of anti-arrhythmic agent Tambocor (flecainide acetate), on June 29 in Japan. more info >> |
|
| Monday, June 22, 2015 |
|
|
U.S. FDA Approves Eisai's Antiepileptic Agent Fycompa as Adjunctive Treatment For Primary Generalized Tonic-Clonic Seizures |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that its U.S. subsidiary Eisai Inc. has received approval from the U.S. Food and Drug Administration (FDA) for an indication expansion regarding the use of its in-house developed antiepileptic agent Fycompa (perampanel hydrate) as an adjunctive treatment of primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy 12 years of age and older. more info >> |
|
| Monday, June 1, 2015 |
|
|
Eisai Receives European Commission Approval of Anticancer Agent Lenvima for Treatment of Advanced Thyroid Cancer Refractory to Radioactive Iodine |
| Eisai Co., Ltd. announced today that its U.K. subsidiary Eisai Europe Ltd. has received approval from the European Commission (EC) for anticancer agent Lenvima (lenvatinib mesylate) in the treatment of adult patients with progressive, locally advanced or metastatic differentiated (papillary, follicular, Hurthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI). more info >> |
|
| Friday, May 29, 2015 |
|
|
AbbVie and Eisai Clear All-Case Surveillance Condition for Approval of HUMIRA, a Fully Human Anti-TNF-alpha Monoclonal Antibody, in the Treatment of Ankylosing Spondylitis |
| AbbVie GK and Eisai Co., Ltd. announced today that they have received notification from Japan's Ministry of Health, Labour and Welfare (MHLW) to the effect that the "all-case surveillance" special drug use-results survey condition required for approval of HUMIRA Pre-filled Syringe 40 mg / 0.8 mL, a fully human anti-TNF-alpha monoclonal antibody formulation, has been lifted for use in patients with ankylosing spondylitis. more info >> |
|
| Wednesday, May 27, 2015 |
|
|
Eisai Submits New Drug Application for Mecobalamin Ultra-High Dose Preparation as Treatment for Amyotrophic Lateral Sclerosis in Japan |
| Eisai Co., Ltd. announced today that it has submitted a new drug application for mecobalamin (development code: E0302) as a treatment for amyotrophic lateral sclerosis (ALS) in Japan. more info >> |
|
|
Eisai Receives Positive CHMP Opinion on Indication Expansion for Antiepileptic Agent Fycompa (Perampanel) as Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures |
| Eisai Co., Ltd. announced today that its U.K. subsidiary Eisai Europe Ltd. has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for the use of Fycompa (perampanel) for the adjunctive treatment of primary generalized tonic-clonic (PGTC) seizures in adult and adolescent patients from 12 years of age with idiopathic generalized epilepsy. more info >> |
|
| Thursday, May 21, 2015 |
|
|
Eisai to Promote Clinical Trial Data Disclosure for The Advancement of Science and Medicine |
| Eisai Co., Ltd. has announced today that, in order to further promote transparency in clinical trial data disclosure, it has determined its policy on clinical trial data disclosure and is making clinical trial data publicly available to researchers via an external website (www.clinicalstudydatarequest.com). more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Cryofocus Medtech: Steady Increase in Revenue and Gross Profit with Solid R&D Expenditures in 2024
Apr 1, 2025 00:42 HKT/SGT
|
|
|
AI Paradox in QA: Twice as Many Testers Fear Job Loss, But Adoption Keeps Climbing 
Mar 31, 2025 23:00 HKT/SGT
|
|
|
Dubai AI Festival returns for highly anticipated second edition as part of the inaugural Dubai AI Week
Mar 31, 2025 21:34 HKT/SGT
|
|
|
Huatai Securities Announces Dividend of RMB 3.7 per 10 Shares Following Record 2024 Performance
Mar 31, 2025 21:33 HKT/SGT
|
|
|
GF Securities Announces its 2024 Interim Results
Mar 31, 2025 21:33 HKT/SGT
|
|
|
Transforming Customer Experiences: Insights from Team Marksmen's CX Transformation Conclave
Mar 31, 2025 21:30 HKT/SGT
|
|
|
Vibe Marketing Tech Fest 2025 Will Focus on Convergence and Conversions
Mar 31, 2025 21:26 HKT/SGT
|
|
|
Local designer brands featured at 'Fashion Hong Kong Pop-up Salon' in Milan
Mar 31, 2025 21:20 HKT/SGT
|
|
|
Huatai Securities Reports Record 2024 Earnings and Advancement in Internationalization
Mar 31, 2025 21:18 HKT/SGT
|
|
|
Asiaray Achieves Net Profit Turnaround of RMB10.4 Million in 2024
Mar 31, 2025 16:52 HKT/SGT
|
|
|
Wuling Motors (00305.HK) Achieves a Surge of 115.6% in Net Profit Attributable to Shareholders for 2024
Mar 31, 2025 16:30 HKT/SGT
|
|
|
Fosun's Core Businesses Stay Firm Despite One-off Non-cash Loss
Mar 31, 2025 16:05 HKT/SGT
|
|
|
Five NTT Group Companies and Biome Inc. Start Joint Development of Large-scale Estimation Technology for Vegetation and Organisms using Satellite Image Data
Mar 31, 2025 15:43 JST
|
|
|
Yunkang's Revenue Proportion from Joint Construction Business for Medical Institution Alliances and Special Testing Items Continue to Grow in 2024
Mar 31, 2025 14:31 HKT/SGT
|
|
|
Avantor Recognized with Two Prestigious Awards at Asia-Pacific Biopharma Excellence Awards 2025
Mar 31, 2025 11:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
